Table 1: Characteristics of rubella, parvovirus B19 and varicella-zoster virus infections in the UK
| Rubella | Parvovirus B19 | Varicella-zoster | |
|
Proportion susceptible in young adult females |
1-2% |
40-50% |
10% |
|
Infectivity - risk transmission from close contact (household attack rate) |
High(90%) |
Medium (50%) |
High(70-90%) |
|
Risk of intrauterine transmission by(gestational age) |
11-16 weeks - 55% |
5-16 weeks - 15% |
28-36 weeks - 25% |
|
Risk of adverse fetal outcome |
11-16 weeks - 20% |
Congenital varicella syndrome: |
|
|
Risk of adverse outcome for mother |
Arthritis |
Arthritis |
Pneumonitis. Case fatality rate for mother estimated at 1/1000 infections in pregnancy |
|
Available Interventions and benefits |
Termination of pregnancy |
Fetal hydrops - intrauterine transfusion reduces odds of death to 0.14 |
ZIG to mother and neonate attenuates illness. Aciclovir within24 hrs of rash onset for mother. Aciclovir for infected neonates |
|
Incubation period |
14-21 days |
13-18 days |
14-21 days |
|
Infectivity period (days pre and post rash onset) |
7 days pre to 10 days post onset of rash |
10 days pre to day of onset of rash |
2 days pre onset of rash until cropping has ceased and all lesions crusted |
|
Number of infections in pregnancy |
Currently rare |
1 in 400 pregnancies (ref 18) or seroconversion of 1.5 -13% per annum among susceptible |
Exposure use of VZIG- 590-785 women per year, 1996-1999, England and Wales
Estimate 2-3 infections per 1000 pregnancies or 2000 maternal infections per year |
|
Terminations of pregnancy |
1995-96 - 18 |
Unknown - not recommended |
Unknown |
|
Babies with congenital infection (proven) |
1994-96 - 20 |
Unknown |
Unknown |
|
Babies with congenital damage (proven) |
1994-96 - 19 |
Unknown |
Unknown |
|
Babies with congenital infection (estimate) |
Rare (see text) |
See below |
30 neonates at risk of severe neonatal infection per year in UK |
|
Babies with congenital damage (estimate) |
Rare (see text) |
2-8 fetal hydrops per 100,000 pregnancies (14-56 cases per year in UK ) 12-48 per 100,000 spontaneous abortion (84-336 cases per year in UK ) |
10 per year, England and Wales |
*This data is extracted from the November 2000 guidance
Last reviewed: 11 December 2008
Topics Menu
- Executive Summary
- Background
- The risk of different rash illnesses in pregnancy
- Laboratory Investigations
- Antibody Screening
- Investigation of a pregnant patient with a non-vesicular rash illness
- The pregnant patient in contact with a non-vesicular rash illness
- Management of proven infection (with rubella, parvovirus, measles, enterovirus, infectious mononucleosis)
- Management of vesicular rash (varicella/herpes zoster) in pregnancy
- Management of vesicular rash (varicella/herpes-zoster) exposure in pregnancy
- Management of neonates exposed to vesicular (varicella/herpes zoster)
- The "continuously exposed" female in the first 20 weeks of pregnancy (e.g. school teachers)
- Information that should be provided to a pregnant woman
